Jun 03, 2022
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
Jun 01, 2022
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
May 27, 2022
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
May 04, 2022
Immutep Presents New and Significant Data from the AIPAC Study
Apr 28, 2022
Immutep Quarterly Activities Report
Apr 27, 2022
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
Mar 29, 2022
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
Mar 23, 2022
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022
Mar 18, 2022
Immutep to Present Biomarker and Multivariate Analysis from Phase IIb AIPAC Study in Metastatic Breast Cancer at ESMO’s Breast Cancer Congress 2022
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
Mar 09, 2022
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer
Feb 24, 2022
Immutep Appoints Lucy Turnbull as Non-Executive Director
